Pacific Edge Limited (PFGTF) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pacific Edge Limited, a leader in cancer diagnostics, announced a steady financial performance for the first half of 2024, despite uncertainties surrounding Medicare. The company is anticipating potential growth catalysts, including a favorable Medicare policy decision and new pricing recommendations for its Cxbladder tests. While revenue slightly declined compared to the previous year, the strategic focus remains on profitable markets and the economic value of its diagnostic tools.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
